The protocol for our ongoing Pivotal Study for the aXess hemodialysis graft has been published in the Journal of Vascular Access, and can be accessed here: https://pubmed.ncbi.nlm.nih.gov/37165650/. The Pivotal Study is a prospective, single-arm, [...]

aXess, Xeltis’ restorative vascular access graft for hemodialysis, has been successfully implanted in the first patient in Greece, as part of the aXess pivotal trial. The procedure took place at the University Hospital of [...]

aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to standard hemodialysis access treatment EINDHOVEN, The Netherlands – 28 April 2023, Xeltis, a developer [...]

New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing from the LSP Health Economics Fund 2, in series D2 fundraise Use of proceeds [...]

If joining a truly innovative medtech company may be part of your end-of-year resolutions, we have good news for you: Xeltis is hiring! We are expanding our device development and clinical trial programs and [...]

The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh, at the Polymers in Medicine and Biology Workshop, Napa (CA - USA) on Wednesday 30 [...]

Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in New York City this Saturday. In a session on new technologies for vascular access [...]

Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular graft, discussed the study and the significant potential held by Xeltis’ technology in dialysis [...]